NO952294L - Spiropiperidiner og homologer aktiverer frigivelse av veksthormon - Google Patents

Spiropiperidiner og homologer aktiverer frigivelse av veksthormon

Info

Publication number
NO952294L
NO952294L NO952294A NO952294A NO952294L NO 952294 L NO952294 L NO 952294L NO 952294 A NO952294 A NO 952294A NO 952294 A NO952294 A NO 952294A NO 952294 L NO952294 L NO 952294L
Authority
NO
Norway
Prior art keywords
growth hormone
spiropiperidines
homologs
growth
activate
Prior art date
Application number
NO952294A
Other languages
English (en)
Norwegian (no)
Other versions
NO952294D0 (no
Inventor
Meng-Hsin Chen
David B R Johnston
Ravi P Nargund
Arthur A Patchett
James R Tata
Lihu Yang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO952294D0 publication Critical patent/NO952294D0/no
Publication of NO952294L publication Critical patent/NO952294L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
NO952294A 1992-12-11 1995-06-09 Spiropiperidiner og homologer aktiverer frigivelse av veksthormon NO952294L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98932292A 1992-12-11 1992-12-11
PCT/US1993/011137 WO1994019367A1 (fr) 1992-12-11 1993-11-15 Spiro piperidines et composes homologues favorisant la liberation de l'hormone de croissance

Publications (2)

Publication Number Publication Date
NO952294D0 NO952294D0 (no) 1995-06-09
NO952294L true NO952294L (no) 1995-08-10

Family

ID=25535014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952294A NO952294L (no) 1992-12-11 1995-06-09 Spiropiperidiner og homologer aktiverer frigivelse av veksthormon

Country Status (15)

Country Link
US (2) US5578593A (fr)
KR (2) KR100203962B1 (fr)
BR (1) BR1100850A (fr)
CZ (1) CZ151595A3 (fr)
FI (1) FI952862A (fr)
HU (1) HUT73228A (fr)
MY (2) MY131439A (fr)
NO (1) NO952294L (fr)
NZ (1) NZ258429A (fr)
PH (1) PH31427A (fr)
PL (1) PL309332A1 (fr)
RU (1) RU95113347A (fr)
TW (1) TW360639B (fr)
WO (1) WO1994019367A1 (fr)
ZA (2) ZA939274B (fr)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115804B1 (ro) * 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
EP0730578A4 (fr) * 1993-11-24 1997-10-08 Merck & Co Inc Composes contenant un groupe indolyle et leur utilisation pour favoriser la liberation d'hormones(s) de croissance
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU3128195A (en) * 1994-07-20 1996-02-16 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US5656606A (en) * 1995-02-17 1997-08-12 Merck & Co., Inc. Camphor compounds promote release of growth hormone
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
WO1997011697A1 (fr) * 1995-09-26 1997-04-03 Merck & Co., Inc. Piperidines et pyrroolidines de 3-spirolactame, 3-spiroamino, 3-spirolactone et 3-spirobenzopyran permettant de promouvoir la liberation de l'hormone de croissance
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
JPH11513989A (ja) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
US5723616A (en) * 1995-10-27 1998-03-03 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
WO1997022004A1 (fr) 1995-12-13 1997-06-19 Merck & Co., Inc. Dosage des recepteurs secretagogues d'hormones de croissance
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
WO1997022367A1 (fr) * 1995-12-20 1997-06-26 Merck & Co., Inc. Secretagogue d'hormone de croissance radiomarque
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
GB9612276D0 (en) * 1996-06-12 1996-08-14 Merck & Co Inc 4-Spiroindoline piperidines promote release of growth hormone
AU2334097A (en) * 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
WO1997041878A1 (fr) * 1996-05-07 1997-11-13 Merck & Co., Inc. Traitement de troubles de l'humeur, a l'aide d'un secretagogue d'hormone de croissance
EP0900086A4 (fr) * 1996-05-07 2000-01-12 Merck & Co Inc Stimulation du sommeil avec un secretagogue d'hormone de croissance
AU4342097A (en) * 1996-09-13 1998-04-02 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
AU4863397A (en) * 1996-11-05 1998-05-29 Novo Nordisk A/S Use of growth hormone or a growth hormone secretagogue for promoting bone formation
AU5594398A (en) * 1996-12-09 1998-07-03 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5803398A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
WO1998046220A1 (fr) * 1997-04-14 1998-10-22 Merck & Co., Inc. Polytherapie pour la prevention et le traitement de l'osteoporose
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
US6117880A (en) * 1997-10-30 2000-09-12 Merck & Co., Inc. Somatostatin agonists
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
DE69921611T2 (de) 1998-01-16 2005-11-03 Novo Nordisk A/S Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US6294534B1 (en) * 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2334551A1 (fr) * 1998-06-11 1999-12-16 Merck & Co., Inc. Derives de spiropiperidine en tant qu'agonistes des recepteurs de la melanocortine
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
EP1097170A1 (fr) 1998-07-13 2001-05-09 Merck & Co., Inc. Recepteurs et acides nucleiques en rapport avec un secretagogue d'hormone de croissance
WO2000009538A2 (fr) 1998-08-10 2000-02-24 Merck & Co., Inc. Recepteur de secretagogue d'hormone de croissance canine
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6194402B1 (en) 1998-09-02 2001-02-27 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) * 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU766191B2 (en) 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US20040266802A1 (en) * 1999-06-07 2004-12-30 Alain Calvet Tricyclic analgesics
US6420376B1 (en) * 1999-07-13 2002-07-16 Merck & Co., Inc. Amido spiropiperidines promote the release of growth hormone
WO2001060796A1 (fr) * 2000-02-18 2001-08-23 Meiji Seika Kaisha, Ltd. DERIVES DE PHENOXYALKYLAMINE UTILES EN TANT QU'AGONISTES DU RECEPTEUR OPIOIDE $g(d)
AU4928101A (en) 2000-03-23 2001-10-03 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
US6458790B2 (en) 2000-03-23 2002-10-01 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1159964B1 (fr) 2000-05-31 2009-10-28 Pfizer Products Inc. Utilisation de secrétagogues d'hormones de croissance pour stimuler la motilité gastrointestinale
CA2419310A1 (fr) 2000-08-23 2002-02-28 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine
WO2002076953A1 (fr) * 2001-03-21 2002-10-03 Warner-Lambert Company Llc Nouveaux derives spirotricycliques et utilisation de ces derives en tant qu'inhibiteurs de la phosphodiesterase-7
CA2443938C (fr) 2001-04-18 2010-06-22 R. Richard Goehring Composes de spiroindene et de spiroindane comme ligands opioides utiles pour le traitement de la douleur
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
WO2002094825A1 (fr) * 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7396846B2 (en) * 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
US20040010010A1 (en) * 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
US7132539B2 (en) * 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1297557C (zh) * 2003-04-10 2007-01-31 上海药明康德新药开发有限公司 螺环类模板化合物的制备
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un secretagogue de l'hormone de croissance
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
MXPA06005038A (es) * 2003-11-04 2007-12-12 Elixir Pharmaceuticals Inc Compuestos terapeuticos y usos de los mismos.
GB0328906D0 (en) * 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
GB0328908D0 (en) * 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
EP1789409A4 (fr) * 2004-04-02 2010-09-08 Elixir Pharmaceuticals Inc Sulfonamides et utilisations de ceux-ci
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2008510706A (ja) 2004-08-18 2008-04-10 エリクシアー ファーマシューティカルズ， インコーポレイテッド 成長ホルモン分泌促進物質
NZ553202A (en) * 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
CN101031552B (zh) * 2004-10-28 2010-11-10 三共株式会社 旋光4,4-二取代噁唑烷衍生物及其制备方法
AU2005309365B2 (en) * 2004-11-29 2011-10-06 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
AU2006330866A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ570497A (en) * 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
KR20080094964A (ko) 2006-02-22 2008-10-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101092396B (zh) * 2006-06-20 2010-09-15 上海药明康德新药开发有限公司 螺[1,3-二氢茚-4'-哌啶-1-羧酸]模板化合物的制备方法
US7858790B2 (en) * 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (fr) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulateurs de récepteurs muscariniques
WO2008021545A2 (fr) * 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulateurs des récepteurs muscariniques
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
AU2008205642B2 (en) * 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
EP2155769B1 (fr) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Protection contre la dégénérescence tissulaire
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2207549A1 (fr) * 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulateurs des récepteurs muscariniques
US20100280049A1 (en) * 2007-11-06 2010-11-04 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010009319A2 (fr) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2350010B1 (fr) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Antagonistes d'isonicotinamide des récepteurs de l'orexine
US8927503B2 (en) 2010-07-28 2015-01-06 The University Of Queensland Modulations of protease activated receptors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8546416B2 (en) * 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2013013273A1 (fr) * 2011-07-28 2013-01-31 The University Of Queensland Modulateurs de récepteurs activés par protéase
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
US20150265680A1 (en) 2012-10-24 2015-09-24 Daiichi Sankyo Company, Limited Therapeutic agent for amyotrophic lateral sclerosis
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
CA2926685A1 (fr) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonistes de guanylate cyclase utiles pour la regulation negative de cytokines pro-inflammatoires
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3134408B1 (fr) * 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3644998B1 (fr) * 2017-06-30 2024-04-10 Quixgen, Inc. Nouveaux composés spirolactones
AU2019223014B2 (en) 2018-02-21 2024-10-17 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (fr) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
TW202227417A (zh) 2020-08-18 2022-07-16 美商默沙東藥廠 雙環庚烷吡咯啶之食慾素受體促效劑
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332704D0 (en) * 1983-12-07 1984-01-11 Pfizer Ltd Growth promotants for animals
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone

Also Published As

Publication number Publication date
ZA939274B (en) 1994-08-08
HU9501681D0 (en) 1995-08-28
BR1100850A (pt) 1999-12-07
FI952862A0 (fi) 1995-06-09
CZ151595A3 (en) 1995-12-13
RU95113347A (ru) 1997-06-10
KR950704347A (ko) 1995-11-20
PL309332A1 (en) 1995-10-02
PH31427A (en) 1998-10-29
ZA939272B (en) 1994-08-08
WO1994019367A1 (fr) 1994-09-01
KR950704346A (ko) 1995-11-20
NO952294D0 (no) 1995-06-09
US5578593A (en) 1996-11-26
MY131439A (en) 2007-08-30
HUT73228A (en) 1996-07-29
TW360639B (en) 1999-06-11
NZ258429A (en) 1997-05-26
MY131457A (en) 2007-08-30
KR100203962B1 (ko) 1999-06-15
FI952862A (fi) 1995-06-09
US5536716A (en) 1996-07-16

Similar Documents

Publication Publication Date Title
NO952294L (no) Spiropiperidiner og homologer aktiverer frigivelse av veksthormon
AU5232093A (en) Spiro piperidines and homologs which promote release of growth hormone
KR101996079B1 (ko) 엔테로코커스 패칼리스를 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물
US10463890B2 (en) Method for preparing broccoli with increased sulforaphane content and use of broccoli prepared thereby
NO961865L (no) Piperidiner, pyrrolidiner og heksahydro-1H-azepiner fremmer frigjörelse av veksthormon
RU95107663A (ru) Бензо-конденсированные лактамы, ускоряющие высвобождение соматотропного гормона, способы их получения, способы лечения, композиции
AU5232193A (en) Spiro piperidines and homologs promote release of growth hormone
JPH01502820A (ja) 薬物／化粧品製剤
Arkko et al. A survey of unproven cancer remedies and their users in an outpatient clinic for cancer therapy in Finland
AT515336A1 (de) Vermeidung oxidativer Prozesse und oxidativem Stress
SK89296A3 (en) Fodder and drinkink water additive for improving the resistance to stress and immunity of useful animals
ATE266658T1 (de) Amido-spiropiperidine promovieren die freisetzung von wachstumshormonen
RU2136173C1 (ru) Кормовая добавка
Kenyon Secrets of the koala hospital
SU681598A1 (ru) Способ профилактики и лечени инфекци-ОННыз зАбОлЕВАНий СВиНЕй и пТицы
SU82330A1 (ru) Способ лечени кокцидиоза цыпл т и индюшат
RU1669100C (ru) Способ выращивани птиц
JP2020000229A (ja) 冬虫夏草子実体の生産方法及び冬虫夏草子実体、並びにサプリメント、機能性食品、医薬組成物及びカプセル剤
GB810378A (en) Fungicidal compositions containing griseofulvin